<DOC>
	<DOCNO>NCT00434135</DOCNO>
	<brief_summary>The aim study : ( 1 ) ass safety activity gemcitabine plus Alimta ( pemetrexed ) regimen ( GA regimen ) patient advanced NSCLC patient context randomized trial , ( 2 ) compare GA paclitaxel plus gemcitabine ( PG regimen ) term toxicity QoL</brief_summary>
	<brief_title>Alimta Gemcitabine Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>Patients stage IIIB IV non-small cell lung cancer randomly allocate receive : ( ) PG regimen : paclitaxel 120 mg/sqm follow gemcitabine 1,000 mg/sqm i.v . day 1 &amp; 8 q 3 week ; ( b ) GA regimen : gemcitabine 1,250 mg/sqm i.v . day 1 ( plus folinic acid 350 μg daily orally vitamin B12 1,000 μg i.m . q 9 week ) , pemetrexed ( Alimta® ) 500 mg/sqm i.v . day 8 follow gemcitabine 1,250 mg/sqm , q 3 week .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>1 . Patients histologically cytologically confirm locally advanced ( stage IIIB ) metastatic ( stage IV ) NSCLC 2 . No previous adjuvant palliative chemotherapy 3 . No previous radiotherapy 4 . Presence least one unidimensionally measurable lesion ( Appendix 2 ) 5 . ECOG performance status 0 1 ( Appendix 3 ) 6 . Charlson score ≤ 2 ( Appendix 4 ) 7 . Adequate bone marrow function ( absolute neutrophil count ≥ 2 x 109/L , platelet count ≥ 100 x 109/L , hemoglobin level ≥ 100 g/L ) , adequate liver function ( bilirubin level &lt; two time upper limit normal , AST and/or ALT &lt; three time upper limit normal , prothrombin time &lt; 1.5 time control ) , creatinine clearance ≥ 60 ml/min . 8 . Absence symptomatic CNS metastasis ( patient cerebral metastasis treat brain irradiation may include ) , severe cardiac arrhythmia heart failure , second third degree heart block acute myocardial infarction within 4 month prior study entry . 9 . No major surgery pleurodesis within 14 day prior enrollment . 10 . Life expectancy least 12 week . 11 . No previous concurrent malignancy , except inactive nonmelanoma skin cancer , situ carcinoma cervix , cancer patient diseasefree 5 year . 12 . Written inform consent 1 . Any unstable systemic disease ( include active infection , uncontrolled hypertension , unstable angina , congestive heart failure , serious cardiac arrhythmia require medication , hepatic , renal metabolic disease ) . 2 . Patients clinically significant effusion . 3 . Any malignancy within 5 year could affect therapy evaluation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>gemcitabine</keyword>
	<keyword>pemetrexed</keyword>
	<keyword>non-small cell lung cancer</keyword>
</DOC>